RPRX

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on September 10, 2026, to shareholders of record at the close of business on August 14, 2026. About Royalty Pharma plcFounded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com. Royalty Pharma Investor Relations and Communications+1 (212) [email protected]

NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com. Royalty Pharma Investor Relations and Communications+1 (212) [email protected]

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Royalty Pharma (RPRX), which belongs to the Zacks Medical - Biomedical and Genetics industry. This company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 8.17%. For the last reported quarter, Royalty Pharma came out with earnings of $1.3 per share versus the Zacks Consensus Estimate of $1.22 per share, representing a surprise of 6.56%. For the previous quarter, the company was expected to post earnings of $1.33 per share and it actually produced earnings of $1.46 per share, delivering a surprise of 9.77%. For Royalty Pharma, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Royalty Pharma has an Earnings ESP of +1.76% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #2 (Buy), it shows that another beat is possibly around the corner. With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss. Many companies end up beating the consensus EPS estimate, though this is not the only reason...

Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Hedged Equity Fund”. A copy of the letter can be downloaded here. The Fund invests in high-quality growth companies and mitigates risk by writing call options. Following the late-February strike on Iran, oil prices surged, leading to a risk-off sentiment, boosting energy sector performance. Large-cap technology stocks declined as investors rotated towards smaller companies and more defensive value investments. Market conditions are becoming challenging due to reduced expectations for a Federal Reserve rate cut and increasing geopolitical uncertainty. The Fund returned 0.08% (net) for the quarter, outperforming the S&P 500 Index, which fell 4.33%, and the CBOE S&P 500 BuyWrite Index, which declined 0.92%. At the end of the period, 43% of the portfolio was unhedged, while the remainder was invested in companies with covered call options. In addition, please check the Fund’s top five holdings to know its best picks in 2026. In its first-quarter 2026 investor letter, Meridian Hedged Equity Fund highlighted Royalty Pharma plc (NASDAQ:RPRX). Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical investment company that specializes in acquiring royalty interests and funding innovation in the biopharmaceutical industry. On June 26, 2026, Royalty Pharma plc (NASDAQ:RPRX) closed at $56.23 per share, reflecting a market capitalization of $32.38 billion. Royalty Pharma plc (NASDAQ:RPRX) posted a one-month return of 1.90%, and its shares gained 56.06% over the past 52 weeks. Meridian Hedged Equity Fund stated the following regarding Royalty Pharma plc (NASDAQ:RPRX) in its Q1 2026 investor letter: Royalty Pharma plc (NASDAQ:RPRX) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 42 hedge fund portfolios held Royalty Pharma plc (NASDAQ:RPRX) at the end of the first quarter, up from 39 in the previous quarter. While we acknowledge the potential of Royalty Pharma plc (NASDAQ:RPRX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we cove...

A month has gone by since the last earnings report for Agenus (AGEN). Shares have lost about 9.6% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Agenus due for a breakout? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent catalysts for Agenus Inc. before we dive into how investors and analysts have reacted as of late. Agenus reported first-quarter 2026 earnings of $1.02 per share, missing the Zacks Consensus Estimate of $2.10. A year ago, the company reported a loss of $1.03. The quarter’s revenues totaled $33.7 million, which missed the consensus mark of $129.5 million. The figure, however, rose 40% year over year, supported by BOT+BAL activity through authorized access pathways. In the first quarter, Agenus posted pre-commercial product revenues of $4.6 million, representing realized income from BOT+BAL provided to hospitals and treating physicians under regulatory-authorized early access pathways, including France’s AAC framework and paid named-patient programs where permitted. Non-cash royalty revenues were $29.1 million compared with $23.6 million in the year-ago quarter. The company reported operating income of $15.1 million and net income of $39.2 million in the quarter. Cash and cash equivalents totaled $35 million at March 31, 2026 compared with $3 million in the previous quarter. After quarter-end, Agenus received an additional $11.7 million in net proceeds from sales of common stock under its at-the-market offering program, and it also expects to collect outstanding receivables tied to authorized early access programs during the second quarter. It turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted 118.75% due to these changes. Currently, Agenus has a average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for value investors. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Agenus has...

Royalty Pharma has been on fire lately. In the past six months alone, the company’s stock price has rocketed 46.3%, reaching $55.73 per share. This performance may have investors wondering how to approach the situation. Is now the time to buy Royalty Pharma, or should you be careful about including it in your portfolio? See what our analysts have to say in our full research report, it’s free. We’re happy investors have made money, but we don’t have much confidence in Royalty Pharma. Here are three reasons why RPRX doesn’t excite us, plus one stock we’d rather own. Reviewing a company’s long-term sales performance reveals insights into its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Regrettably, Royalty Pharma’s sales grew at a tepid 2.1% compounded annual growth rate over the last five years. This fell short of our benchmarks. Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right. With just $2.44 billion in revenue over the past 12 months, Royalty Pharma lacks scale in an industry where it matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive. Free cash flow isn’t a prominently featured metric in company financials and earnings releases, but we think it’s telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king. As you can see below, Royalty Pharma’s margin dropped by 2.9 percentage points over the last five years. If its declines continue, it could signal increasing investment needs and capital intensity. Royalty Pharma’s free cash flow margin for the trailing 12 months was 7.8%. Royalty Pharma isn’t a terrible business, but it doesn’t pass our bar. After the recent surge, the stock trades at 10.7× forward P/E (or $55.73 per share). This valuation is reasonable, but the company’s shakier fundamentals present too much downside risk. We’re pretty confident there are superior stocks to buy right now. Let us point you toward an all-weather company...

Royalty Pharma’s first quarter results surpassed Wall Street’s revenue and adjusted EBITDA expectations, driven by robust growth across its diversified royalty portfolio and increased capital deployment. Management attributed these results to double-digit gains in recurring royalty receipts and several new investments in therapies with significant commercial potential. CEO Pablo Legorreta emphasized the impact of recent clinical successes and portfolio expansion, noting, “We delivered 10% growth in portfolio receipts and 13% growth in royalty receipts, driven by the strength of our diversified portfolio.” Is now the time to buy RPRX? Find out in our full research report (it’s free). Revenue: $630.6 million vs analyst estimates of $874.1 million (11% year-on-year growth, 27.9% miss) Adjusted EPS: $1.30 vs analyst estimates of $1.18 (9.4% beat) Adjusted EBITDA: $889 million vs analyst estimates of $816.7 million (141% margin, 8.8% beat) Operating Margin: 89.3%, down from 94% in the same quarter last year Market Capitalization: $22.92 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Hardik Parikh (JPMorgan): Asked about how much of Royalty Pharma’s 2030 portfolio receipt target is supported by current assets. CFO Terrance Coyne said they are confident in exceeding the target, citing strong portfolio developments but did not give specific asset breakdowns. Michael Nedelcovych (TD Cowen): Inquired about leverage after higher capital deployment and the ability to add royalty investments to ramping products. Coyne emphasized low leverage and ample capital capacity, while EVP Marshall Urist explained that additional capital deployment depends on partner options and product milestones. Jason Gerberry (Bank of America): Sought clarity on managing global launch value risk under new pricing policies and differences in IRR expectations for co-funding vs. traditional royalties. Urist noted they model a range of risk scenarios and maintain consistent return expectations across investment structures. Nick Jennings (Goldman Sachs): Asked about portfolio mix changes from increased R&D co-funding and China market progress. Chai...

Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda Announced appointment of Chris Murphy as CFO Announced appointments of Susannah Gray, former CFO of Royalty Pharma, and Owen Hughes, current CEO of XOMA Royalty, to its Board of Directors SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “Following the completion of the spin-off of First Tracks Bio in late April, Anaptys now exclusively manages the financial collaborations for Jemperli and imsidolimab, with streamlined operations requiring limited FTEs, minimal operating expenses and delivering an EBIT margin greater than 95%,” said Daniel Faga, president and chief executive officer. “With Chris Murphy joining as CFO, who brings deep business development and investment banking experience, our priority continues to be to protect our two royalty streams and return their value to shareholders.” GSK Jemperli Financial Collaboration GSK announced strong commercial performance for Jemperli ($313 million/£232 million in Q1 2026 sales, with >40% year-over-year growth1) Anaptys continues to expect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys as early as 2029 at GSK’s peak sales guidance of >$2.7 billion2 Anaptys estimates Sagard will have accrued ~$275 million in royalties and sales milestones through Q1 2026 and anticipates paydown of the remaining ~$325 million non-recourse debt monetization by the end of Q2 20273 Substantial GSK investment in additional monotherapy and potential combination trials for Jemperli, including: AZUR-1 – pivotal Phase 2 – dostarlimab monotherapy in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer Data expected in H2 2026; U.S. FDA Breakthrough Therapy Designation Received an FDA Commissioner’s National Priority Voucher (CNPV) in Nov. 2025 allowing for only a one to two-month sBLA review timeline for US FDA approval AZUR-2 – pivotal Phase 3 – dostarlimab versus standard of care in untreated TN40 or stage III dMMR/ MSI-H resectable colon cancer Data expec...

Delivered 13% growth in recurring royalty receipts, driven by a diversified portfolio and the absorption of the Promacta loss of exclusivity. Strategic pivot toward R&D co-funding with global biopharma aims to unlock a $1 trillion market opportunity, leveraging contra R&D accounting clarity to scale partnerships. Performance attribution highlights the strength of the cystic fibrosis franchise and newer launches like Voranigo and Evrysdi as primary growth engines. Management emphasizes a 'win-win' rationale for co-funding, allowing partners to share risk and expand R&D capacity while Royalty Pharma gains access to high-priority programs. The internalization of management functions is driving cost savings, with operating and professional costs for 2026 expected to be in the range of approximately 5.5% to 6.5% of portfolio receipts. The integration of AI capabilities, led by the new Head of AI, is designed to automate diligence processes and strengthen how the company evaluates and invests in royalties. Increased 2026 full-year guidance assumes 4% to 8% growth in royalty receipts, reflecting strong underlying momentum despite anticipated biosimilar competition for Tysabri. Guidance methodology excludes the benefit of future royalty acquisitions, maintaining a conservative baseline for the current portfolio's performance. Anticipates several new royalty-generating launches in 2026 and 2027, supported by a deep pipeline of transformative therapies in oncology and immunology. Strategic focus on China as a significant future growth avenue, with plans to monetize royalties originating from out-licensing activities to Western multinationals. The 2030 target of approaching $5 billion in portfolio receipts remains on track, supported by both commercial-stage assets and derisked development programs. Announced $1.25 billion in new transactions, including a strategic royalty acquisition for Ziihera, an approved cancer therapy with blockbuster potential. Highlighted 'unprecedented' Phase III results for daraxonrasib in pancreatic cancer, which nearly doubled overall survival compared to chemotherapy. Fitch upgraded the company's credit rating to BBB, reflecting a strengthened balance sheet and a conservative leverage profile of 2.7x on a net basis. The Vertex arbitration timeline has been extended to mid-2027, a delay attributed solely to the availability of the arbitrati...

Image source: The Motley Fool. Wednesday, May 6, 2026 at 8:00 a.m. ET Chief Executive Officer and Chairman of the Board — Pablo Legorreta Chairman, Partnering and Investments — Christopher Hite EVP, Head of Research and Investments — Marshall Urist EVP, Chief Financial Officer — Terrance Coyne Need a quote from a Motley Fool analyst? Email [email protected] Pablo Legorreta, Chief Executive Officer and Chairman of the Board; Chris Hite, Chairman, Partnering and Investments; Marshall Urist, EVP, Head of Research and Investments; and Terry Coyne, EVP, Chief Financial Officer. Pablo will discuss the key highlights, after which Chris will discuss the growing opportunity for R&D co-funding. Marshall will then provide a portfolio update and Terry will review the financials. Following concluding remarks from Pablo, we will hold a Q&A session. And with that, I'd like to turn the call over to Pablo. Pablo Legorreta: Thank you, George, and welcome to everyone on the call. I am happy to report a strong start to 2026 as we execute towards our goal to be the premier capital allocator in life sciences, with consistent compounding growth. Slide 5 summarizes our strong business momentum in the first quarter. Starting with the financials, we delivered 10% growth in portfolio receipts, our top line and 13% growth in royalty receipts, which are our recurring cash flows. The sustained double-digit momentum was driven by strength of our diversified portfolio. We also maintained strong returns in our business with returns on invested capital of around 14% and returns on invested equity of around 20%. By combining strong growth and attractive returns, we're confident that we have a clear path to drive shareholder value creation. Turning to capital allocation. We had a busy quarter with $1.25 billion of announced transactions on 3 attractive therapies, while capital deployed was in excess of $0.5 billion. We also repurchased 1 million shares for $50 million in the quarter and increased our dividend by 7%. Moving to our portfolio. We're thrilled to see a number of positive clinical and regulatory updates, including the extraordinary Phase III results for Revolution Medicines' daraxonrasib in pancreatic cancer and FDA approval of Denali's Avlayah in Hunter syndrome. We also expanded our portfolio through R&D co-funding agreements with Teva, which we discussed on our previous earnings call a...

Royalty Pharma reported a “strong start” to 2026 with 10% growth in portfolio receipts and 13% growth in royalty receipts, deployed more than $0.5 billion of capital (with $1.25 billion announced), repurchased 1 million shares for $50 million, raised the dividend 7%, and raised full‑year 2026 guidance to $3.325–$3.45 billion. The company struck material deals and saw major portfolio catalysts, including a $250 million funding for Zymeworks’ Ziihera royalty (peak sales modeled >$2 billion) and a $500 million synthetic royalty investment in Revolution Medicines’ daraxonrasib after trial data showed a near doubling of overall survival, driving expectations for substantial peak royalties. Balance-sheet strength and strategic positioning underpin growth: cash of $586 million, investment‑grade debt of $9.2 billion with leverage ~2.9x and an undrawn $1.8 billion revolver (Fitch upgrade to BBB), while the firm is expanding into R&D co‑funding (first‑quarter deals with J&J and Teva ~ $1 billion) to capture a large biopharma R&D opportunity. Interested in Royalty Pharma PLC? Here are five stocks we like better. How Royalty Pharma Prints Cash Without Biotech's Biggest Risks Royalty Pharma (NASDAQ:RPRX) reported what executives described as a “strong start” to 2026, driven by double-digit growth in cash receipts, active capital deployment and a series of clinical and regulatory developments across its portfolio, according to management’s remarks on the company’s first-quarter earnings call. Chief Executive Officer and Chairman Pablo Legorreta said the company delivered “10% growth in portfolio receipts” and “13% growth in royalty receipts,” which he characterized as Royalty Pharma’s recurring cash flows. Legorreta added that performance was supported by the “strength of our diversified portfolio,” and said the company maintained “returns on invested capital of around 14% and returns on invested equity of around 20%.” → 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries 1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data Legorreta also highlighted capital deployment during the quarter, citing “$1.25 billion of announced transactions on three attractive therapies,” with capital deployed “in excess of $0.5 billion dollars.” He said Royalty Pharma repurchased 1 million shares for $50 million and increased its dividend by 7% during the quarter. C...

Royalty Pharma (RPRX) came out with quarterly earnings of $1.3 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +6.56%. A quarter ago, it was expected that this company would post earnings of $1.33 per share when it actually produced earnings of $1.46, delivering a surprise of +9.77%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Royalty Pharma, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $925 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.79%. This compares to year-ago revenues of $839 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Royalty Pharma shares have added about 30.5% since the beginning of the year versus the S&P 500's gain of 6%. While Royalty Pharma has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Royalty Pharma was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (S...